Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS

Gareth P Gregory; Michael Dickinson; Costas K Yannakou; Jonathan Wong; Piers Blombery; Greg Corboy; Lev Kats; Tim M E Crozier; Beena Kumar; H Miles Prince; Stephen S Opat; Jake Shortt

doi:10.1097/HS9.0000000000000187

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS

Hemasphere. 2019 Mar 1;3(2):e187. doi: 10.1097/HS9.0000000000000187. eCollection 2019 Apr.

Authors

Gareth P Gregory^{1

2}, Michael Dickinson^{3

4}, Costas K Yannakou^{3

4

5}, Jonathan Wong^{1

2}, Piers Blombery^{3

4}, Greg Corboy^{1

2}, Lev Kats^{4

6}, Tim M E Crozier^{1

2}, Beena Kumar^{1

2}, H Miles Prince^{3

4

5}, Stephen S Opat^{1

2}, Jake Shortt^{1

2

4}

Affiliations

¹ Monash Health, Clayton, Victoria, Australia.
² School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
³ Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Parkville, Victoria, Australia.
⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
⁵ Department of Molecular Oncology and Cancer Immunology, Epworth Healthcare, East Melbourne, Victoria, Australia.
⁶ Research Division, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.

No abstract available

Publication types

Case Reports